血三甲基胺N-氧化物 (TMAO):与认知,神经成像和痴呆症的关联
Amber Yaqub1, Dina Vojinovic1,2, Meike W Vernooij1,3
1Department of Epidemiology, Erasmus MC, University Medical Center, PO Box 2040, Rotterdam, CA, 3000, the Netherlands.
Alzheimer's research & therapy
|May 20, 2024
概括
三甲基胺N氧化物 (TMAO) 和其前体,如胆,研究了它们对大脑健康的影响. 较高的胆,而不是TMAO,与认知能力下降和大脑变化有关,除了那些患有脏问题的人.
科学领域:
- 神经科学是一个神经科学.
- 代谢学 代谢学 代谢学
- 心血管健康 心血管健康
背景情况:
- 肠道衍生代谢物三甲基胺N氧化物 (TMAO) 和其前体 (贝他因,卡尼丁,胆,脱氧卡尼丁) 与心血管疾病风险有关.
- TMAO及其前体与认知功能,神经成像标志物和痴呆症之间的关系尚未得到充分理解.
研究的目的:
- 研究血TMAO及其前体与认知之间的关联.
- 检查TMAO及其前体与结构性脑MRI标记物之间的联系.
- 评估与TMAO及其前体相关的发生性痴呆的风险.
主要方法:
- 基于人口的鹿特丹研究,共3,143名参与者进行认知,2,047名参与者进行MRI,2,517名参与者进行痴呆风险.
- 使用了多变量回归和Cox比例危险模型.
- 敏感性分析包括功能受损,药物使用和性别分层.
主要成果:
- 血TMAO与认知,神经成像或整体痴呆症没有关联.
- 高血胆与较差的认知,大脑缩和大脑小血管疾病标志物相关.
- 较高的卡尼丁与较低的白质超强度体积有关.
- 只有在功能受损的个体中,TMAO会增加痴呆症的风险.
结论:
- 血胆,而不是TMAO,与认知衰退,大脑缩和大脑小血管疾病有关.
- 这些发现突显了TMAO前体与大脑健康之间的复杂相互作用.
- 需要进一步研究以了解涉及TMAO及其前体的肠-大脑机制.
相关概念视频
01:26Alzheimer's Disease: Overview
465
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
465
01:22Alzheimer's Disease: Treatment
180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120
01:30Dementia
111
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
111